Tauroursodeoxycholic acid

WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT

Retrieved on: 
Tuesday, January 17, 2023
API, WLLW, Sandhill, TUDCA, Active ingredient, Amyotrophic lateral sclerosis, Cannabinoid, TSX, Tauroursodeoxycholic acid, Organic acid, UDCA, Primary sclerosing cholangitis, Willow, Growth, Research, Ursodeoxycholic acid, ALS, Fine chemical

This represents the continuation of the project, the first phase of which the Company announced May 31, 2022.

Key Points: 
  • This represents the continuation of the project, the first phase of which the Company announced May 31, 2022.
  • Sandhill is partnered with a large-cap, multi-national healthcare company and the targeted product is manufacture of the large volume API, ursodeoxycholic acid (UDCA).
  • In this next phase of development, the Company anticipates several hundred thousand U.S. dollars in research fees, along with a milestone payment later this year for initial production batches.
  • Upon successful completion, it is expected that Willow's proprietary, optimized enzyme will be taken toward commercialization for the end market active pharmaceutical ingredients ("APIs"), where Willow will receive additional milestone and production-based royalty payments.